Tagrisso (osimertinib) is a targeted cancer therapy designed for treating non-small cell lung cancer (NSCLC) with specific mutations. It works by inhibiting the activity of the EGFR protein that promotes cancer cells’ growth and survival. Clinical trials proved that osimertinib is highly effective in treating advanced NSCLC patients, particularly those with the T790M mutation. A phase 3 trial found that osimertinib was significantly more effective and better-tolerated than chemotherapy at prolonging progression-free survival. Besides, Tagrisso has been studied in combination with other cancer therapies, indicating even better outcomes for advanced NSCLC patients. Its targeted mechanism and high efficacy make it a valuable option for treating this type of cancer.